Shaily Engineering: Pioneering Growth in GLP-1 Drug Delivery Devices
Growth in Healthcare Revenue
Shaily Engineering is witnessing considerable growth in its healthcare segment, primarily driven by the production of GLP-1 drug delivery devices such as pen injectors and auto-injectors. Revenue in this sector grew 139%, outperforming other segments. This change underscores Shaily's evolving focus on high-margin healthcare solutions, positioning the company to benefit from the escalating demand for diabetes and obesity treatments.
Market Driving Factors
- Global GLP-1 drug market expected to exceed $100 billion by 2030.
- Shaily's strategic partnerships ensure steady contracts.
- Expansion planned for Abu Dhabi plant to increase production capacity.
This shift towards healthcare not only enhances margins but also underscores Shaily's commitment to high-precision manufacturing within the medical space.
Financial Outlook
- Healthcare revenue: Rs 104.3 crore, up 139% in Q3 FY26.
- EBITDA growth: 43% with expanding margins.
- Strong institutional interest, with Smallcap World Fund increasing stake.
Shaily is positioned successfully within the growing healthcare landscape, bolstered by its commitment to high-quality drug delivery device manufacturing. Investor confidence remains strong as the company adapts to changing market demands.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.